Medicenna Therapeutics Corp. (TSX:MDNA)
1.075
+0.025 (2.38%)
Apr 25, 2025, 3:59 PM EDT
Medicenna Therapeutics Employees
Medicenna Therapeutics had 16 employees as of March 31, 2024. The number of employees did not change compared to the previous year.
Employees
16
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-1.68M CAD
Market Cap
84.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Green Thumb Industries | 4,800 |
dentalcorp Holdings | 10,200 |
Sienna Senior Living | 12,263 |
Trulieve Cannabis | 6,000 |
Extendicare | 23,000 |
Curaleaf Holdings | 5,519 |
WELL Health Technologies | 1,507 |
Cronos Group | 459 |
Medicenna Therapeutics News
- 4 weeks ago - Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 2 months ago - Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones - GlobeNewsWire
- 2 months ago - Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025 - GlobeNewsWire
- 4 months ago - Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire
- 5 months ago - Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study - GlobeNewsWire
- 5 months ago - Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference - GlobeNewsWire
- 5 months ago - Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) - GlobeNewsWire
- 5 months ago - Medicenna Therapeutics GAAP EPS of -C$0.05 - Seeking Alpha